N-(1)-boc-5-硝基吲唑 | 129488-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: N-(1)-boc-5-硝基吲唑
• 英文名称: 5-nitro-indazole-1-carboxylic acid tert-butyl ester
• 英文别名: 5-nitro-indazole-1-carboxylic acid tertbutyl ester；tert-butyl 5-nitro-1H-indazole-1-carboxylate；5-nitroindazole-1-carboxylic acid tert-butyl ester；5-nitro-indazole-1-carboxylic acid t-butyl ester；tert-butyl 5-nitroindazole-1-carboxylate
• CAS: 129488-09-1
• 化学式: C₁₂H₁₃N₃O₄
• 分子量: 263.253
• InChiKey: YXAJFAVMXBRTMU-UHFFFAOYSA-N

物化性质

• 熔点：
  128-130 °C
• 沸点：
  406.1±37.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  89.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 5-nitroindazole-1-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 5-nitroindazole-1-carboxylate
CAS number: 129488-09-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H13N3O4
Molecular weight: 263.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(1)-boc-5-硝基吲唑 在 palladium on activated charcoal 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 1,2-二氯乙烷 为溶剂， 30.0~80.0 ℃ 、344.75 kPa 条件下， 反应 65.0h， 生成 5-[1-(3-carboxymethyl-benzyl)-piperidin-3-ylamino]-indazole-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  NOVEL ROCK INHIBITORS

  摘要：

  本发明涉及新型激酶抑制剂，其化学式为(I)，其中X是氧、—NH—或直接键；Y是—NH—或直接键；n是从0到4的整数；m是从0到4的整数；Cy代表由饱和（多）环组成的二价基团，包括融合的、双的、螺环或桥接的碳环和杂环；特别是从以下组中选择：化学式（II），Ar是从包括化学式（III）的组中选择；R2是氢或甲基；R8是氢、甲基、卤素或炔基；R1是芳基或杂芳基，更具体地是ROCK抑制剂，包含此类抑制剂的组合物，特别是药品，以及此类抑制剂在治疗和预防疾病中的用途。特别是，本发明涉及新型ROCK抑制剂，包含此类抑制剂的组合物，特别是药品，以及此类抑制剂在治疗和预防疾病中的用途。此外，本发明还涉及治疗方法以及使用所述化合物在制造药品中的应用，用于治疗包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病等多种治疗适应症。

  公开号：

  US20140057942A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 以 四氢呋喃 、 5-硝基吲唑 、 mineral oil 为溶剂， 以100%的产率得到N-(1)-boc-5-硝基吲唑
  参考文献：
  名称：

  N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity

  摘要：

  本申请描述了CCR3的调节剂，其化学公式为(I)： 1 或其药用可接受的盐形式，用于预防哮喘和其他过敏性疾患。

  公开号：

  US20030032654A1

文献信息

• Indazole compounds useful as protein kinase inhibitors
  申请人：——

  公开号：US20040009968A1

  公开（公告）日：2004-01-15

  The present invention provides compounds of formula I: 1 or a pharmaceutically acceptable derivative thereof, wherein R 1 , R 2 , V 1 , V 2 , and V 3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.

  本发明提供了公式I:1的化合物或其药用可接受的衍生物，其中R1、R2、V1、V2和V3如规范中描述。这些化合物是蛋白激酶的抑制剂，特别是AKT、PKA、PDK1、p70S6K或ROCK激酶的抑制剂，这些哺乳动物蛋白激酶参与增殖性和神经退行性疾病。该发明还提供了包括该发明的化合物的药物组合物以及利用这些组合物在治疗各种疾病中的方法。
• Mild Deprotection of<i>tert</i>‐Butyl Carbamates of NH‐Heteroarenes under Basic Conditions
  作者：Manas Chakrabarty、Taraknath Kundu、Yoshihiro Harigaya

  DOI：10.1080/00397910600634480

  日期：2006.6

  Abstract Aqueous methanolic potassium carbonate under reflux has been demonstrated to be a highly effective deprotective agent for the tert‐butyl carbamates of indoles, indazoles, carbazole, thiazoloindole, and pyrrole. The method is a mild one and is particularly expeditious for NH‐heteroarenes bearing electron‐withdrawing groups.

  摘要 回流下的甲醇碳酸钾水溶液已被证明是吲哚、吲唑、咔唑、噻唑并吲哚和吡咯的氨基甲酸叔丁酯的高效脱保护剂。该方法是一种温和的方法，尤其适用于带有吸电子基团的 NH-杂芳烃。
• Synthesis of Novel N-Aryl-1H-indazolamines from Amino-1H-indazoles and Arylboronic Acids
  作者：Udutha Kumara Swamy、H. Rama Mohan、U. Viplava Prasad

  DOI：10.14233/ajchem.2014.16794

  日期：——

  An efficient and high-yielding synthesis of N-aryl-1H-indazolamines from amino-1H-indazole and arylboronic acids are described. In this study a series of novel N-aryl-1H-indazolamines (1a-i) were synthesized using arylboronic acids and amino-1H-indazoles (3a-c).

  本研究描述了以氨基-1H-吲唑和芳基硼酸为原料高效高产合成 N-芳基-1H-吲唑胺的方法。本研究使用芳基硼酸和氨基-1H-吲唑（3a-c）合成了一系列新型 N-芳基-1H-吲唑胺（1a-i）。
• Microwave-assisted N-Boc deprotection under mild basic conditions using K3PO4·H2O in MeOH
  作者：Srinivasa Reddy Dandepally、Alfred L. Williams

  DOI：10.1016/j.tetlet.2008.12.074

  日期：2009.3

  A simple and efficient method for the deprotection of secondary Boc-protected amino compounds under mild basic conditions using K3PO4·H2O in MeOH assisted by microwave irradiation has been presented.

  提出了一种简单有效的方法，在中等碱性条件下，采用K 3 PO 4 ·H 2 O的MeOH溶液，通过微波辐照，在Boc保护的仲氨基化合物上进行脱保护。
• [EN] NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS<br/>[FR] NOUVEAUX DERIVES DE CYANOPYRIDINE UTILES DANS LE TRAITEMENT DU CANCER ET D'AUTRES TROUBLES
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2004078747A1

  公开（公告）日：2004-09-16

  This invention relates to novel diaryl ureas of Formula (I), pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper­proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

  本发明涉及公式（I）的新型二芳基脲、包含这些化合物的药物组合物以及将这些化合物或组合物用于治疗增殖过度和血管生成障碍的方法，作为单一药物或与细胞毒性治疗联合使用。